Starpharma Holdings (ASX:SPL) Common Stock: A$240.75 Mil (As of Dec. 2025)


ASX:SPL Starpharma Holdings Ltd ASX:SPL
53 GF Score
Price A$0.70
GF Value A$0.43
Valuation Significantly Overvalued
! 3 Warning Signs
View Full Analysis

What is Starpharma Holdings Common Stock?

Starpharma Holdings ASX:SPL +0.72% 53 Common Stock is A$240.75 Mil as of Dec. 2025. GuruFocus rates ASX:SPL with a GF Score™ of 53/100 and a GF Value™ of A$0.43 (Significantly Overvalued). The stock has 3 warning signs investors should review.

Starpharma Holdings's quarterly common stock stayed the same from Dec. 2024 (A$240.75 Mil) to Jun. 2025 (A$240.75 Mil) and stayed the same from Jun. 2025 (A$240.75 Mil) to Dec. 2025 (A$240.75 Mil).

Starpharma Holdings's annual common stock increased from Jun. 2023 (A$240.72 Mil) to Jun. 2024 (A$240.75 Mil) but then stayed the same from Jun. 2024 (A$240.75 Mil) to Jun. 2025 (A$240.75 Mil).

Starpharma Holdings Common Stock Historical Data

* Premium members only.

The historical data trend for Starpharma Holdings's Common Stock can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Starpharma Holdings Common Stock Chart

Starpharma Holdings Annual Data
Trend Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23 Jun24 Jun25
Common Stock
Get a 7-Day Free Trial Premium Member Only Premium Member Only 240.63 240.67 240.72 240.75 240.75

Starpharma Holdings Semi-Annual Data
Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Common Stock Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 240.72 240.75 240.75 240.75 240.75
ASX:SPL
53GF Score
Starpharma Holdings Ltd ASX:SPL
Common Stock is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Starpharma Holdings Common Stock Calculation

Common stock is listed on the Balance Sheet at the par value of the total shares outstanding of a company.

The par value of common stocks is meaningless. It is usually set at an absurdly low number.

Frequently Asked Questions Learn more about Common Stock →
What does a Common Stock of A$240.75 Mil mean?
Starpharma Holdings (ASX:SPL) has a Common Stock of A$240.75 Mil as of Dec. 2025. Common Stock is the par value of a company's shares outstanding, as listed on the balance sheet. View historical data on Starpharma Holdings and its competitors.
Is Starpharma Holdings' Common Stock too high?
Starpharma Holdings' current Common Stock is A$240.75 Mil. Overall, Starpharma Holdings has a GF Score™ of 53/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Starpharma Holdings' Common Stock compare to VRTX and REGN?
Starpharma Holdings' Common Stock of A$240.75 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Common Stock for a Biotechnology company?
A good Common Stock depends on the Biotechnology industry context. However, Common Stock should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Common Stock mean?
A high Common Stock can signal that a stock is expensive relative to its fundamentals. Common Stock is the par value of a company's shares outstanding, as listed on the balance sheet. View historical data on Starpharma Holdings and its competitors. Starpharma Holdings's current Common Stock is A$240.75 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Starpharma Holdings stock overvalued right now?
Based on GuruFocus' analysis, Starpharma Holdings (ASX:SPL) is currently considered Significantly Overvalued. The stock's GF Value™ is A$0.43, compared to a current price of A$0.70 — trading 62.8% above its estimated fair value. The current Common Stock is A$240.75 Mil. Starpharma Holdings' overall GF Score™ is 53/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Common Stock calculated?
Common Stock is calculated from a company's financial statements. For Starpharma Holdings (ASX:SPL), the current Common Stock is A$240.75 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Starpharma Holdings (ASX:SPL) Overvalued in 2026?

Based on GuruFocus' analysis, Starpharma Holdings stock appears to be overvalued. The current stock price of A$0.70 is trading 62.8% above its estimated GF Value™ of A$0.43. GuruFocus considers Starpharma Holdings to be Significantly Overvalued.

Key valuation signals for ASX:SPL:

  • Common Stock: A$240.75 Mil
  • GF Value™: A$0.43 vs. price of A$0.70 (62.8% above fair value)
  • GF Score™: 53/100 with 3 warning signs

No single metric tells the full story. See the ASX:SPL stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Starpharma Holdings Business Description

Address 4-6 Southampton Crescent, Abbotsford, Melbourne, VIC, AUS, 3067
Starpharma Holdings Ltd is an Australia-based company engaged in the research, development, and commercialization of dendrimer products for pharmaceutical, life science, and other applications. It focuses on the development of VivaGel for the management and prevention of bacterial vaginosis and as a condom coating, and VIRALEZE, an antiviral nasal spray.
53GF Score

Get the complete analysis for ASX:SPL

Common Stock is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

A$0.70
Price
A$0.43
GF Value